- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.11. | BioNTech to buy Biotheus, gaining control of cancer bispecific | ||
| 12.11. | GSK partners with Flagship startup to hunt for Parkinson's drugs | ||
| 12.11. | Biotech investors, including Third Rock, pump $100M into a startup's genetic medicine for ALS | ||
| 12.11. | Neurogene hits a setback in the clinic, one week after raising funds | ||
| 12.11. | AstraZeneca, Daiichi revise approval plans for Enhertu successor | ||
| 11.11. | On Wall Street, 'flat out' failure of AbbVie schizophrenia drug leaves analysts stunned | ||
| 11.11. | FDA approves new CAR-T competitor to Gilead's Tecartus | ||
| 11.11. | FDA lifts pause on Novavax flu vaccine trials | ||
| 11.11. | AbbVie's $9B bet collapses as closely watched schizophrenia drug fails studies | ||
| 11.11. | Cigna confirms it is not pursuing Humana acquisition | ||
| 11.11. | Thinking inside the box: How SmartLabs is driving new collaborations to support the life science industry in global innovation hubs | ||
| 11.11. | Fueling accelerated drug development in autoimmune diseases with a modality-agnostic approach | ||
| 11.11. | 7 steps to selecting the right global central lab | ||
| 08.11. | Kalaris to go public via reverse merger with AlloVir | ||
| 08.11. | Athira exploring strategic alternatives after Alzheimer's failure | ||
| 08.11. | Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value | ||
| 08.11. | What RFK Jr.'s influence on Trump could mean for pharma | ||
| 07.11. | Moderna earnings beat forecasts, but analysts question whether sales spike will last | ||
| 07.11. | Sarepta scraps a Duchenne drug as gene therapy sales rise | ||
| 07.11. | With Trump victorious, biotech industry's focus turns to his plans for FDA, FTC | ||
| 06.11. | Novo sees Wegovy sales rise as supply constraints ease | ||
| 06.11. | Acadia sells speedy drug review voucher for $150M | ||
| 06.11. | Moderna said to shuffle sales leadership; Vertex records first Casgevy sale | ||
| 06.11. | An RNAi renaissance is creating a new generation of startups | ||
| 05.11. | Cancer cell therapy from Arcellx, Gilead shows promise in early data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
